Results of Operations and Financial Condition On August 3, 2026, Ainos, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2026. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1. The information in this Item in this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchang…

Changes in Registrant’s Certifying Accountant. Following the expiration of the engagement with YCM CPA INC. (“YCM”), the Company’s independent registered public accounting firm, on July 9, 2026, the Company dismissed YCM as the Company’s independent registered public accounting firm. On the same day, the audit committee of the board of directors of the Company (the “Audit Committee”) engaged DLEE Accountancy, Inc. (“ DLEE ”) as the Company’s new independent registered public accounting firm,…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On July 3, 2026, Ainos, Inc. (the “Company”) entered into a General Agreement for Omnibus Credit Lines (the “Credit Lines Agreement”) with CTBC Bank Co., Ltd. (“CTBC Bank”), a commercial bank organized under the laws of the Republic of China (Taiwan). Pursuant to the Credit Lines Agreement, CTBC Bank has made available to the Company a short-term unsecured credit facility (the “C…

Results of Operations and Financial Condition On May 13, 2026, Ainos, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2026. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1. The information in this Item in this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange…

Results of Operations and Financial Condition On March 30, 2026, Ainos, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information contained in Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabil…

Unregistered Sales of Equity Securities On December 30, 2025, following the approval by the board of directors of Ainos, Inc. (the “Company”), the Company issued 1,160,000 shares of common stock (“AIMD Shares”), par value $0.01 (the “Common Stock”) to its wholly owned subsidiary, ScentAI Inc. (“ScentAI”), in exchange for 116,000,000 shares of common stock to be issued by ScentAI. The AIMD Shares issued to ScentAI shall have no voting power, for so long as they are owned by a wholly owned subs…

Results of Operations and Financial Condition On November 13, 2025, Ainos, Inc. (the “Company”) reported its financial results for the quarter ended September 30, 2025. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1. The information in this Item in this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the…

Entry into a Material Definitive Agreement. As previously reported, on August 1, 2021, Ainos, Inc. ( the “ Company ”) entered into a five-year product development agreement (the “ Product Development Agreement ”) with Taiwan Carbon Nano Technology Corporation (“ TCNT ”), as amended on January 9, 2024, July 8, 2024, and October 16, 2024, to co-develop pharmaceutical, medical device and other products defined in the agreement. TCNT controls the company via its majority interest in Ainos Inc., a…

Other Events. As previously reported, on May 31, 2024, Ainos, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC as placement agent (the “Placement Agent”) to offer and sell shares of its common stock, par value $0.01 per share (“Common Stock”), having an aggregate offering price of up to $1,353,197 from time to time through the Placement Agent. On July 11, 2024, the Company filed a prospectus supplement under the Agreement…

Results of Operations and Financial Condition On August 13, 2025, Ainos, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2025. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1. The information in this Item in this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchan…

Changes in Registrant’s Certifying Accountant. On July 30, 2025, KCCW Accountancy Corp. (“KCCW”) resigned as independent registered public accounting firm of Ainos, Inc. (the “Company”), as it is exiting the public company audit practice. On July 31, 2025, the audit committee of the board of directors of the Company (the “Audit Committee”) engaged YCM CPA Inc. (“YCM”) as the Company’s new independent registered public accounting firm, as described below. During our most recent fiscal year and…

Other Events. On June 24, 2025, Ainos, Inc., a Texas corporation, issued a press release announcing the formation a legally binding strategic partnership with Kenmec Mechanical Engineering Co., Ltd. A copy of the press release is furnished herewith as Exhibit 99.1.

Results of Operations and Financial Condition On May 12, 2025, Ainos, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2025. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1. The information in this Item in this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange…

Entry Into a Material Definitive Agreement. As previously reported, on March 13, 2023, Ainos, Inc., a Texas corporation (“Ainos”, “we” or the “Company”), entered into a Convertible Note Purchase Agreement, dated as of March 13, 2023 (the “Agreement”), with Li-Kuo Lee, in the principal amount of $1,000,000 (the “Principal Amount”). Pursuant to the Agreement, the Company issued a Convertible Promissory Note to Li-Kuo Lee in the Principal Amount (the “Convertible Note”). The Principal Amount and…

Entry Into a Material Definitive Agreement. As previously reported, on March 13, 2023, Ainos, Inc., a Texas corporation (“Ainos”, “we” or the “Company”), entered into a Convertible Note Purchase Agreement, dated as of March 13, 2023 (the “Agreement”), with ASE Test, Inc. (“ASE Test”), a shareholder of the Company’s controlling shareholder, Ainos Inc., a Cayman Islands corporation, in the principal amount of $2,000,000 (the “Principal Amount”). Pursuant to the Agreement, the Company issued Con…

Results of Operations and Financial Condition On March 7, 2025, Ainos, Inc. (the “Company”) reported its financial results for the fiscal year ended December 31, 2024. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1. The information in this Item in this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “…

Other Events. On November 27, Ainos, Inc. ( the “ Company ”) signed a Memorandum of Understanding (“ MOU ”) with Taiwan Tanabe Seiyaku Co., Ltd. (“ Taiwan Tanabe ”), a corporation majority-owned by Mitsubishi Tanabe Pharma Corporation. The MOU outlines a collaboration on the manufacturing and promotion of the Company’s Sjögren’s syndrome drug, VELDONA®, to meet market demand. Under the terms of the MOU, Taiwan Tanabe desires to become the exclusive marketer, manufacturer, and marketing author…

Entry into a Material Definitive Agreement. As previously reported, on August 1, 2021, Ainos, Inc. ( the “ Company ”) entered into a five-year product development agreement (the “ Product Development Agreement ”) with Taiwan Carbon Nano Technology Corporation (“ TCNT ”), as amended on January 9, 2024 and July 8, 2024, to co-develop pharmaceutical, medical device and other products defined in the agreement. TCNT controls the company via its majority interest in Ainos Inc., a Cayman Islands cor…

Entry into a Material Definitive Agreement. Patent License Agreement On August 6, 2024, Ainos, Inc., a Texas corporation (the “ Company ”) entered into a patent license agreement (the “ License Agreement ”) with Taiwan Carbon Nano Technology Corporation (“ TCNT ”), as an effort to bolster the Company’s AI Nose and point-of-care testing (POCT) technologies while preserving cash. As of August 5, 2024, prior to TCNT entering into the License Agreement, TCNT controlled, via its majority interest…

Executive Vice President of Operations — Lawrence K. Lin: Mr. Lin transitioned out of his executive role and no longer serves as an officer.

Note Conversion As previously reported, on September 25, 2023, the Company entered into a securities purchase agreement with Lind Global Fund II LP (“Lind”) and issued a senior secured convertible promissory note, as amended on January 23, 2024 (the “Note”) to Lind. On August 5, 2024, the Company fully prepaid the remaining outstanding principal of the Note, totaling $1.67 million. The prepayment was made with $1,439,754 in cash and $224,842 through the issuance of 382,384 shares of Common St…

Results of Operations and Financial Condition On August 5, 2024, Ainos, Inc. (the “Company”) reported its financial results for the second quarter ended June 30, 2024. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1. The information in this Item in this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 15, 2024, Ainos, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Cap…

Entry into a Material Definitive Agreement. As previously reported, on August 1, 2021, Ainos, Inc. ( the “ Company ”) entered into a five-year product development agreement (the “ Product Development Agreement ”) with Taiwan Carbon Nano Technology Corporation (“ TCNT ”). TCNT holds a majority share of Ainos Inc., a Cayman Islands corporation, which holds approximately 39% of the voting power of the Company as of July 8, 2024. Pursuant to the Product Development Agreement, the parties will co-…

Results of Operations and Financial Condition. On May 13, 2024, Ainos, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The information in this